Evidence map›Paper›PMID 28424652›Full record

ReviewFrontiers in neurology2017

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?

Michael K Leuchter, Elissa J Donzis, Carlos Cepeda, Aimee M Hunter, Ana María Estrada-Sánchez, Ian A Cook, Michael S Levine, Andrew F Leuchter

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael K LeuchterDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Elissa J DonzisDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Carlos CepedaDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Aimee M HunterDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Ana María Estrada-SánchezDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Ian A CookDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Michael S LevineDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Andrew F LeuchterDavid Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major focus in development of novel therapies for Huntington's disease (HD) is identification of treatments that reduce the burden of mutant

Indexed as

biomarkerselectrophysiologyhumanhuntingtin aggregatesHuntington’s diseasemousemutant huntingtinquantitative electroencephalography

Identifiers

PMID28424652
PMCPMC5371600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.